Effect of CpG methylation at different sequence context on acrolein- and BPDE-DNA binding and mutagenesis

Carcinogenesis

Volumn 34, Issue 1, 2013, Pages 220-227

  Wang, Hsiang Tsui ^a   Weng, Mao Wen ^a   Chen, Wen Chi ^a   Yobin, Michael ^a   Pan, Jishen ^b   Chung, Fung Lung ^b   Wu, Xue Ru ^a   Rom, William ^a   Tang, Moon Shong ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACROLEIN; BENZO[A]PYRENE; CCAAT ENHANCER BINDING PROTEIN DELTA; PROTEIN P53; TOBACCO SMOKE;

ARTICLE; BINDING SITE; CONTROLLED STUDY; CPG ISLAND; DNA BINDING; DNA METHYLATION; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN CELL; LUNG CANCER; LUNG FIBROBLAST; MUTAGENESIS; PRIORITY JOURNAL;

7,8-DIHYDRO-7,8-DIHYDROXYBENZO(A)PYRENE 9,10-OXIDE; ACROLEIN; BASE SEQUENCE; CELLS, CULTURED; CPG ISLANDS; DNA; DNA ADDUCTS; DNA METHYLATION; DNA PRIMERS; HUMANS; MOLECULAR SEQUENCE DATA; MUTAGENS; POLYMERASE CHAIN REACTION;

EID: 84872134415     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgs323     Document Type: Article

References (42)

1. Stevens, J.F. et al. (2008) Acrolein: sources, metabolism, and biomolecular interactions relevant to human health and disease. Mol. Nutr. Food Res., 52, 7-25.
2. Chung, F.L. et al. (1996) Lipid peroxidation as a potential endogenous source for the formation of exocyclic DNA adducts. Carcinogenesis, 17, 2105-2111.
3. Kehrer, J.P. et al. (2000) The molecular effects of acrolein. Toxicol. Sci., 57, 6-15.
4. Ghilarducci, D.P. et al. (1995) Fate and effects of acrolein. Rev. Environ. Contam. Toxicol., 144, 95-146.
5. Sladek, N.E. (1972) Therapeutic efficacy of cyclophosphamide as a function of inhibition of its metabolism. Cancer Res., 32, 1848-1854.
6. Cohen, S.M. et al. (1992) Acrolein initiates rat urinary bladder carcinogenesis. Cancer Res., 52, 3577-3581.
7. Comes, R., et al. (2002) Concise International Chemical Assessment Document No 43. World Health Organization, Geneva.
8. Chung, F.L. et al. (1984) Formation of cyclic 1, N2-propanodeoxyguanosine adducts in DNA upon reaction with acrolein or crotonaldehyde. Cancer Res., 44, 990-995.
9. Wang, H.T. et al. (2012) Effect of carcinogenic acrolein on DNA repair and mutagenic susceptibility. J. Biol. Chem., 287, 12379-12386.
10. Tang, M.S. et al. (2011) Acrolein induced DNA damage, mutagenicity and effect on DNA repair. Mol. Nutr. Food Res., 55, 1291-1300.
11. Kanuri, M. et al. (2002) Error prone translesion synthesis past gammahydroxypropano deoxyguanosine, the primary acrolein-derived adduct in mammalian cells. J. Biol. Chem., 277, 18257-18265.
12. Kawanishi, M. et al. (1998) Molecular analysis of mutations induced by acrolein in human fibroblast cells using supF shuttle vector plasmids. Mutat. Res., 417, 65-73.
13. Minko, I.G. et al. (2003) Translesion synthesis past acrolein-derived DNA adduct, gamma -hydroxypropanodeoxyguanosine, by yeast and human DNA polymerase eta. J. Biol. Chem., 278, 784-790.
14. Sanchez, A.M. et al. (2003) Comparative evaluation of the bioreactivity and mutagenic spectra of acrolein-derived alpha-HOPdG and gamma-HOPdG regioisomeric deoxyguanosine adducts. Chem. Res. Toxicol., 16, 1019-1028.
15. VanderVeen, L.A. et al. (2001) Evaluation of the mutagenic potential of the principal DNA adduct of acrolein. J. Biol. Chem., 276, 9066-9070.
16. Wang, H.T. et al. (2009) Mutagenicity and sequence specificity of acrolein-DNA adducts. Chem. Res. Toxicol., 22, 511-517.
17. Yang, I.Y. et al. (2002) Mutagenesis by acrolein-derived propanodeoxyguanosine adducts in human cells. Biochemistry, 41, 13826-13832.
18. Yang, I.Y. et al. (2001) Responses to the major acrolein-derived deoxyguanosine adduct in Escherichia coli. J. Biol. Chem., 276, 9071-9076.
19. Yang, I.Y. et al. (2002) Genotoxic mechanism for the major acroleinderived deoxyguanosine adduct in human cells. Chem. Res. Toxicol., 15, 160-164.
20. Yang, I.Y. et al. (2003) Mammalian translesion DNA synthesis across an acrolein-derived deoxyguanosine adduct. Participation of DNA polymerase eta in error-prone synthesis in human cells. J. Biol. Chem., 278, 13989-13994.
21. Feng, Z. et al. (2006) Acrolein is a major cigarette-related lung cancer agent: Preferential binding at p53 mutational hotspots and inhibition of DNA repair. Proc. Natl. Acad. Sci. U.S.A., 103, 15404-15409.
22. Fujioka, K. et al. (2006) Determination of toxic carbonyl compounds in cigarette smoke. Environ. Toxicol., 21, 47-54.
23. Hoffman, D., et al. (1990) The Handbook of Experimental Pharmacology. Springer, Heidelberg, 70-74.
24. Kligerman, S. et al. (2011) Epidemiology of lung cancer in women: risk factors, survival, and screening. AJR. Am. J. Roentgenol., 196, 287-295.
25. Hecht, S.S. et al. (2010) Elevated levels of volatile organic carcinogen and toxicant biomarkers in Chinese women who regularly cook at home. Cancer Epidemiol. Biomarkers Prev., 19, 1185-1192.
26. Saffiotti, U. et al. (1968) A method for the experimental induction of bronchogenic carcinoma. Cancer Res., 28, 104-124.
27. Denissenko, M.F. et al. (1996) Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53. Science, 274, 430-432.
28. Denissenko, M.F. et al. (1998) Slow repair of bulky DNA adducts along the nontranscribed strand of the human p53 gene may explain the strand bias of transversion mutations in cancers. Oncogene, 16, 1241-1247.
29. Smith, L.E. et al. (2000) Targeting of lung cancer mutational hotspots by polycyclic aromatic hydrocarbons. J. Natl. Cancer Inst., 92, 803-811.
30. Canella, K.A. et al. (2000) Mutation spectra in supF: approaches to elucidating sequence context effects. Mutat. Res., 450, 61-73.
31. Tang, M.S. (ed) (1996) Technologies for Detection of DNA Damage and Mutation. Plwnum, New York, 139-152.
32. Maxam, A.M. et al. (1980) Sequencing end-labeled DNA with base-specific chemical cleavages. Meth. Enzymol., 65, 499-560.
33. Johnson, W.S. et al. (1995) Selective recognition of the m5CpG dinucleotide sequence in DNA by mitomycin C for alkylation and cross-linking. Bioorg. Med. Chem., 3, 851-860.
34. Tornaletti, S. et al. (1995) Complete and tissue-independent methylation of CpG sites in the p53 gene: implications for mutations in human cancers. Oncogene, 10, 1493-1499.
35. Denissenko, M.F. et al. (1997) Cytosine methylation determines hot spots of DNA damage in the human P53 gene. Proc. Natl. Acad. Sci. U.S.A., 94, 3893-3898.
36. Chen, J.X. et al. (1998) Carcinogens preferentially bind at methylated CpG in the p53 mutational hot spots. Cancer Res., 58, 2070-2075.
37. Li, V.S. et al. (2001) The effect of C(5) cytosine methylation at CpG sequences on mitomycin-DNA bonding profiles. Bioorg. Med. Chem., 9, 863-873.
38. Gonzalgo, M.L. et al. (1997) Mutagenic and epigenetic effects of DNA methylation. Mutat. Res., 386, 107-118.
39. Krawczak, M. et al. (1998) p53 mutations, benzo[a]pyrene and lung cancer. Mutagenesis, 13, 319-320.
40. Cooper, D.N., et al. (1993) Human Gene Mutation. BIOS Scientific Publishers: Oxford, UK.
41. Krawczak, M. et al. (1995) Somatic spectrum of cancer-associated single basepair substitutions in the TP53 gene is determined mainly by endogenous mechanisms of mutation and by selection. Hum. Mutat., 5, 48-57.
42. Yoon, J.H. et al. (2001) Methylated CpG dinucleotides are the preferential targets for G-to-T transversion mutations induced by benzo[a]pyrene diol epoxide in mammalian cells: similarities with the p53 mutation spectrum in smoking-associated lung cancers. Cancer Res., 61, 7110-7117.